Abstract：
BACKGROUND: Acne vulgaris is a common chronic inflammatory disorder of the pilosebaceous unit, characterized by papules, pustules and/or nodules manifesting primarily on the face and/or upper back that can leave scars, post-inflammatory hyperpigmentation (PIH) and erythema (PIE).
OBJECTIVE: To evaluate the anti-inflammatory properties of a protein-free sap extruded from Rhealba® oat plantlets and a Garcinia mangostana extract on Cutibacterium acnes-induced inflammation in vitro and assess the tolerability and efficacy of a dermocosmetic product containing these actives in subjects with mild-to-moderate acne.
METHODS: Monocyte-derived dendritic cells (Mo-DCs) from acne patients were stimulated with a planktonic culture of C. acnes and cytokine production was evaluated before and after addition of the test extracts by RT-PCR and ELISA. The clinical study was conducted in subjects with mild-to-moderate acne who applied the product to their face and upper back twice-daily for 2 months.
RESULTS: Cutibacterium acnes-induced IL-6, IL-12p40, IL-10 and TNFα synthesis was reduced by the addition of the Garcinia mangostana extract and oat sap in vitro. The clinical study included 54 subjects. The 2-month, twice-daily application of the test product to the whole face and acne-affected areas on the upper back was well tolerated. It led to significant decreases in the number of retentional (-21% for 69% of subjects at D57) and inflammatory (-35% for 79% of subjects at D57) acne lesions, as well as a decrease in Global Acne Evaluation severity scores (2.5 at D1, 2.2 at D29 and 2.1 at D57). The dermatologist also rated the product as effective or very effective in most subjects with PIE (82%; n = 33/40) and PIH (70%; n = 8/11) at D57.
CONCLUSIONS: The actives demonstrated anti-inflammatory effects in vitro, and the dermocosmetic product showed good clinical efficacy and tolerability in subjects with mild-to-moderate acne, supporting the use of this product in acne management.
OBJECTIVE: To evaluate the anti-inflammatory properties of a protein-free sap extruded from Rhealba® oat plantlets and a Garcinia mangostana extract on Cutibacterium acnes-induced inflammation in vitro and assess the tolerability and efficacy of a dermocosmetic product containing these actives in subjects with mild-to-moderate acne.
METHODS: Monocyte-derived dendritic cells (Mo-DCs) from acne patients were stimulated with a planktonic culture of C. acnes and cytokine production was evaluated before and after addition of the test extracts by RT-PCR and ELISA. The clinical study was conducted in subjects with mild-to-moderate acne who applied the product to their face and upper back twice-daily for 2 months.
RESULTS: Cutibacterium acnes-induced IL-6, IL-12p40, IL-10 and TNFα synthesis was reduced by the addition of the Garcinia mangostana extract and oat sap in vitro. The clinical study included 54 subjects. The 2-month, twice-daily application of the test product to the whole face and acne-affected areas on the upper back was well tolerated. It led to significant decreases in the number of retentional (-21% for 69% of subjects at D57) and inflammatory (-35% for 79% of subjects at D57) acne lesions, as well as a decrease in Global Acne Evaluation severity scores (2.5 at D1, 2.2 at D29 and 2.1 at D57). The dermatologist also rated the product as effective or very effective in most subjects with PIE (82%; n = 33/40) and PIH (70%; n = 8/11) at D57.
CONCLUSIONS: The actives demonstrated anti-inflammatory effects in vitro, and the dermocosmetic product showed good clinical efficacy and tolerability in subjects with mild-to-moderate acne, supporting the use of this product in acne management.
摘要：
背景：寻常痤疮是毛囊皮脂腺常见的慢性炎症性疾病，以丘疹为特征，脓疱和/或结节主要表现在面部和/或上背部，可能留下疤痕，炎症后色素沉着（PIH）和红斑（PIE）。
目的：评估从Rhealba®燕麦小植株中挤出的无蛋白汁液和藤黄提取物在体外对痤疮葡糖杆菌诱导的炎症的抗炎特性，并评估耐受性和功效。含有这些活性物质的皮肤化妆品产品在轻度至中度痤疮的受试者中。
方法:用痤疮梭菌浮游培养物刺激来自痤疮患者的单核细胞衍生的树突状细胞(Mo-DC),并通过RT-PCR和ELISA在添加测试提取物之前和之后评价细胞因子的产生。临床研究是在患有轻度至中度痤疮的受试者中进行的，该受试者每天两次将产品应用于面部和上背部，持续2个月。
结果：通过在体外添加藤黄提取物和燕麦汁，可以减少痤疮杆菌诱导的IL-6，IL-12p40，IL-10和TNFα的合成。临床研究包括54名受试者。2个月,每天两次将测试产品应用于整个面部和上背部受痤疮影响的区域，耐受性良好。它导致保留性（D57时69％的受试者为-21％）和炎性（D57时79％的受试者为-35％）痤疮病变的数量显着减少，以及全球痤疮严重程度评分下降（D1为2.5，D29为2.2，D57为2.1）。皮肤科医生还评价该产品在D57时在大多数患有PIE(82%;n=33/40)和PIH(70%;n=8/11)的受试者中有效或非常有效。
结论：活性物质在体外表现出抗炎作用，皮肤化妆品在轻度至中度痤疮患者中显示出良好的临床疗效和耐受性，支持在痤疮管理中使用本产品。
目的：评估从Rhealba®燕麦小植株中挤出的无蛋白汁液和藤黄提取物在体外对痤疮葡糖杆菌诱导的炎症的抗炎特性，并评估耐受性和功效。含有这些活性物质的皮肤化妆品产品在轻度至中度痤疮的受试者中。
方法:用痤疮梭菌浮游培养物刺激来自痤疮患者的单核细胞衍生的树突状细胞(Mo-DC),并通过RT-PCR和ELISA在添加测试提取物之前和之后评价细胞因子的产生。临床研究是在患有轻度至中度痤疮的受试者中进行的，该受试者每天两次将产品应用于面部和上背部，持续2个月。
结果：通过在体外添加藤黄提取物和燕麦汁，可以减少痤疮杆菌诱导的IL-6，IL-12p40，IL-10和TNFα的合成。临床研究包括54名受试者。2个月,每天两次将测试产品应用于整个面部和上背部受痤疮影响的区域，耐受性良好。它导致保留性（D57时69％的受试者为-21％）和炎性（D57时79％的受试者为-35％）痤疮病变的数量显着减少，以及全球痤疮严重程度评分下降（D1为2.5，D29为2.2，D57为2.1）。皮肤科医生还评价该产品在D57时在大多数患有PIE(82%;n=33/40)和PIH(70%;n=8/11)的受试者中有效或非常有效。
结论：活性物质在体外表现出抗炎作用，皮肤化妆品在轻度至中度痤疮患者中显示出良好的临床疗效和耐受性，支持在痤疮管理中使用本产品。
